KIT and hematologic disorder: Ex vivo autologous hematopoietic stem cell (HSC) genetherapy hasprovided new therapies for the treatment of hematological disorders.However, these therapies have several limitations owing to the manufacturingcomplexities and toxicity resulting from required conditioning regimens.Here, we developed a c-kit (CD117) antibody-targeted lipid nanoparticle(LNP) that, following a single intravenous injection, can deliverRNA (both siRNA and mRNA) to HSCs in vivo in rodents.This targeted delivery system does not require stem cell harvest,culture, or mobilization of HSCs to facilitate delivery.